How to sell Synchron shares

Start with what you hold

There are three kinds of Synchron position. An SPV interest is a unit in a vehicle that bought into a round, governed by the vehicle’s operating agreement. Directly held preferred, bought by a fund or investor, is a share on the company’s ledger and needs the company’s approval to move. Employee equity — options or RSUs, exercised or not — follows the company’s plan; unexercised options cannot be sold on their own. Pull your subscription agreement, the SPV’s operating agreement and any side letter before talking to anyone, including us.

How Synchron liquidity actually works

Synchron has not published a void-transfer notice, and no tender has been announced. Its stock carries the standard controls — company approval for any transfer and a right of first refusal — and consent is the first diligence item. The recorded market is all one structure: every one of the 10 Synchron secondaries recorded on PrivateMarketView from December 2025 to June 2026 was an SPV interest, all on preferred. An SPV sale moves a unit between members of a vehicle, with the manager’s consent, while the shares stay put. That makes the vehicle — its terms, its costs and the evidence that it holds approved shares — as important as the company in any sale.

What the position is worth

The reference round is the $200 million Series D announced November 6, 2025, led by Double Point Ventures with ARCH Venture Partners, Khosla Ventures and Bezos Expeditions; a company spokesperson put the valuation at nearly $1 billion. The live numbers — the current mark, the round history, the recorded trade aggregates and the investor book — are maintained on the Synchron data page, published from PrivateMarketView, the data platform behind this site. None of those references is your price. An SPV unit prices on the vehicle as much as the company, and a pre-approval medical device prices on how buyers read the trial. That number comes from buyers.

The trial question

The Series D was raised to fund a pivotal study, and a successful pivotal study is what allows a premarket approval filing with the FDA. Medical-device valuations tend to move in steps around milestones like these, and in both directions. A holder deciding whether to wait is deciding whether to carry a binary event, with the full position or with part of it. There is no IPO filed or discussed publicly, and no tender, so the outcome of the trial — and the time it takes — is the real clock. Selling part before and keeping the rest is a common way to hold exposure without carrying all of it. Which is right turns on your own concentration, cash needs and tax position; a desk should inform that decision, never make it.

How a sale runs through this desk

Tell the desk what you hold — an SPV unit (and which vehicle), direct preferred, or vested equity — and your timing. We confirm what the position can do first: the vehicle’s transfer and consent terms, the evidence that it holds approved shares, and the company’s rules for anything held directly. The position then goes to buyers without your name on it. You are not named until you agree to proceed, there is no fee to ask, and the fee on a brokered sale is quoted on your file in writing — how the fee works. The close runs through a FINRA-registered broker-dealer; our CRDs are on the about page.

Common questions

Can I sell my Synchron shares?

Usually, yes — within the company’s process, and first be precise about what you hold. Every Synchron secondary recorded on PrivateMarketView over the past year was an SPV interest, so many sellers hold a unit in a vehicle rather than shares. Synchron has not published a void-transfer warning, but its stock carries the standard private-company controls: a transfer needs company approval and typically faces a right of first refusal.

Does Synchron run tender offers?

None has been announced. Its rounds — most recently the $200 million Series D in November 2025 — have been primary capital for clinical work and commercialization, not purchases from existing holders. If a tender is announced, understand it before doing anything else.

What should I check about the SPV I hold?

Three things. That the vehicle actually holds Synchron shares the company issued or approved — ask for the subscription evidence. The vehicle’s own transfer terms: manager consent, a right of first refusal for other members, any lock-up. And its economics — management fee and carry — because a buyer prices your unit net of both.

How does the pivotal trial affect my decision?

Directly. Synchron’s Series D was raised to fund a pivotal study of its Stentrode brain-computer interface, which must succeed before the company can file for FDA premarket approval. Clinical milestones move medical-device valuations in steps, in both directions, and buyers price that uncertainty. A seller deciding whether to wait is deciding whether to hold through a binary event, which is a concentration question first.

What is Synchron stock worth right now?

The live reference point is the Series D in November 2025, which a company spokesperson put at a valuation of nearly $1 billion, and the recorded SPV market. The current mark, the round history and the trade aggregates are on the Synchron data page, published from PrivateMarketView, the data platform behind this site. None of those is your price.

Should I hold instead of selling?

That is a real choice with real costs. There is no IPO filed or discussed publicly and no tender, and the company’s value is tied to trial results and a regulatory decision still ahead. Selling part and keeping the rest is a common middle path for a holder who wants exposure to the outcome without carrying all of it. The right answer turns on your concentration, cash needs and taxes.

Premier Alternatives is not affiliated with Synchron or any of its investors. This page describes public information and market behavior as of November 3, 2026; it is not legal, tax, medical or investment advice, and a sale of private securities deserves an hour with your tax adviser before it closes.

Read next

• The Synchron data page — valuation, rounds, trade aggregates, the investor book.
• Direct transfer, SPV or forward — the structures compared, and what selling an SPV interest involves.
• The process, step by step — the eight steps of any private-share sale.
• Every route to liquidity, compared — tender, broker, marketplace, forward, or wait.